Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Miyako Sudo"'
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 122:577-587
TAK-063 is currently being developed to treat schizophrenia. In this study, we investigated the absorption, distribution, metabolism and excretion (ADME) properties of TAK-063 using several paradigms. Following oral administration of TAK-063 at 0.3 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b238bf084d9cf7b24bbe832d76f68fa7
https://doi.org/10.1111/bcpt.12964
https://doi.org/10.1111/bcpt.12964
Publikováno v:
Drug Metabolism and Disposition. 45:734-736
We evaluated the long-term stability of hepatocytes stored in the vapor phase of liquid nitrogen for their viability, cytochrome P450 (CYP) 1A2 activity, CYP3A4/5 activity, uridine diphosphate-glucuronosyl transferase (UGT) activity, sulfotransferase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1f5f4e742dfb1e0e37c93abbeed303
https://doi.org/10.1124/dmd.117.075234
https://doi.org/10.1124/dmd.117.075234
Autor:
Tomoaki Higuchi, Yuu Moriya, Liping Pan, Ronald D. Lee, Akifumi Kogame, Masami Nonaka, Yoshihiko Tagawa, Miyako Sudo
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(4)
The absorption, distribution, metabolism, and excretion of fasiglifam were investigated in rats, dogs, and humans. The absolute oral bioavailability of fasiglifam was high in all species (>76.0%). After oral administration of [14C]fasiglifam, the adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42dded6cd63cd8aa2ffc322eeaacabf1
https://pubmed.ncbi.nlm.nih.gov/29557709
https://pubmed.ncbi.nlm.nih.gov/29557709
Autor:
Junzo Takahashi, Miyako Sudo, Yutaka Kiyota, Takahiro Kondo, Satoru Asahi, Naohiro Kawaguchi, Mitsuhiro Nishihara
Publikováno v:
Drug Metabolism and Disposition. 40:249-258
Animal pharmacokinetic studies of sipoglitazar, a novel antidiabetic agent, showed that the deethylated metabolite (M-I) and the glucuronide conjugate of sipoglitazar (sipoglitazar-G) appeared to be the key metabolites in the elimination process. M-I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45de8be8e2e80eb747aff48bd0d2d86e
https://doi.org/10.1124/dmd.111.040105
https://doi.org/10.1124/dmd.111.040105
Autor:
Masao Okumura, Akihiko Gemma, Hideo Ogata, Miyako Sudo, Shoji Kudoh, Kozo Yoshimori, Keiko Morii, Kozui Kida
Publikováno v:
International Journal of Clinical Medicine. :444-451
Objective: Hypersensitivity pneumonitis (HP) may be a complex syndrome rather than a single, uniform disease entity. The problems associated with HP treatment include a lack of awareness of primary care procedures and scarcity of recent information r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e4f26c7fb867aefd7c2e770e10f519
https://doi.org/10.4236/ijcm.2011.24074
https://doi.org/10.4236/ijcm.2011.24074
Autor:
Miho Karube, Tunee Yamato, Hitoshi Koji, Ken Yoshihara, Takako Ohtuka, Kimimasa Nakabayashi, Noriko Ikegaya, Sohko Kawashima, Toshihiro Fukuoka, Yoshihiro Arimura, Akira Yamada, Miyako Sudo
Publikováno v:
Modern Rheumatology. 19:420-426
Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70973681db5289eb6bac62764e0c62ef
https://doi.org/10.1007/s10165-009-0182-0
https://doi.org/10.1007/s10165-009-0182-0
Autor:
Yoshihiko Tagawa, Mitsuhiro Nishihara, Hidenori Kamiguchi, Naohiro Kawaguchi, Yoshihiro Maeshiba, Miyako Sudo, Yutaka Kiyota, Junzo Takahashi, Takahiro Kondo, Satoru Asahi
Publikováno v:
Drug metabolism and pharmacokinetics. 27(2)
Summary: Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ. The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys respe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56745d037935e6b80d080e10067c185b
https://pubmed.ncbi.nlm.nih.gov/22123126
https://pubmed.ncbi.nlm.nih.gov/22123126
Autor:
Kogame, Akifumi1 akifumi.kogame@takeda.com, Lee, Ronald2, Pan, Liping2, Sudo, Miyako1, Nonaka, Masami1, Moriya, Yuu1, Higuchi, Tomoaki1, Tagawa, Yoshihiko1
Publikováno v:
Xenobiotica. Apr2019, Vol. 49 Issue 4, p433-445. 13p.
Autor:
Tohyama, Kimio1 Kimio.tohyama@takeda.com, Sudo, Miyako1, Morohashi, Akio1, Kato, Suguru1, Takahashi, Junzo1, Tagawa, Yoshihiko1
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. Jun2018, Vol. 122 Issue 6, p577-587. 11p.
Publikováno v:
Drug Metabolism Reviews. Nov2011 Supplement 2, Vol. 43, p37-211. 175p.